I. Research topic: Complex clinico-pathological and molecular analysis of meningiomas in order to identify and experimentally validate novel prognostic biomarkers and therapeutic targets
Our research group is engaged in the complex clinicopathological and molecular characterization of the most common primary central nervous system tumors, meningiomas. Our primary goal is to identify novel prognostic biomarkers and therapeutic targets, and to experimentally validate them in vitro and in vivo. Our current research focuses primarily on the role of the epigenetic regulator EZH2 molecule and metabolic plasticity.
Leader: Dr. Bálint Scheich
Publications:
- Szőke P, Sztankovics D, Dankó T, Mohammed AA, Váncza L, Papp G, Márk Á, Bödör C, Sebestyén A, Dezső K, Scheich B. EZH2 overexpression is associated with aggressive behavior and promotes cell proliferation in CNS WHO grade 3 meningiomas. Neurooncol Adv. 2025 Jun 5;7(1):vdaf112. doi: 10.1093/noajnl/vdaf112. PMID: 40718644; PMCID: PMC12290454.
- Bedics G, Szőke P, Bátai B, Nagy T, Papp G, Kránitz N, Rajnai H, Reiniger L, Bödör C, Scheich B. Novel, clinically relevant genomic patterns identified by comprehensive genomic profiling in ATRX-deficient IDH-wildtype adult high-grade gliomas. Sci Rep. 2023 Oct 27;13(1):18436. doi: 10.1038/s41598-023-45786-w. PMID: 37891325; PMCID: PMC10611758.
- Bedics G, Csóka M, Reiniger L, Varga E, Liptai Z, Papp G, Bekő A, Cervi C, Bödör C, Scheich B. Novel actionable ROS1::GIT2 fusion in non-Langerhans cell histiocytosis with central nervous system involvement. Acta Neuropathol. 2023 Jan;145(1):153-156. doi: 10.1007/s00401-022-02520-6. Epub 2022 Nov 23. PMID: 36416966; PMCID: PMC9807475.
- Bedics G, Kotmayer L, Zajta E, Hegyi LL, Brückner EÁ, Rajnai H, Reiniger L, Bödör C, Garami M, Scheich B. Germline MUTYH mutations and high-grade gliomas: Novel evidence for a potential association. Genes Chromosomes Cancer. 2022 Oct;61(10):622-628. doi: 10.1002/gcc.23054. Epub 2022 May 21. PMID: 35545820; PMCID: PMC9541377.